Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Patient Understanding

    - PMLiVE

    Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    Eli Lilly’s Omvoh recommended by CHMP to treat Crohn’s disease in adults

    The drug is already approved in the EU to treat ulcerative colitis, another form of inflammatory bowel disease

    - PMLiVE

    J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

    Inflammatory bowel disease affects approximately four million people in Europe

    - PMLiVE

    Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

    Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

    The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

    - PMLiVE

    Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

    Inflammatory bowel disease affects around ten million people worldwide

    - PMLiVE

    AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

    The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

    - PMLiVE

    AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

    Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

    - PMLiVE

    AbbVie announces positive results from head-to-head study of Skyrizi in Crohn’s disease

    The late-stage trial has been evaluating the IL-23 inhibitor against Johnson & Johnson’s Stelara

    - PMLiVE

    Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

    About ten million people worldwide are affected by inflammatory bowel disease

    - PMLiVE

    AbbVie shares positive results from head-to-head study of Skyrizi in Crohn’s disease

    The late-stage study has been evaluating the drug against Johnson & Johnson’s Stelara

    - PMLiVE

    AbbVie’s Rinvoq receives FDA approval for Crohn’s disease

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links